Statistics from Altmetric.com
Spiriva or tiotropium bromide (long-acting muscarinic receptor antagonist) is licensed for maintenance bronchodilator treatment in the management of chronic obstructive pulmonary disease (COPD) in 55 countries. Singh and colleagues conducted a systematic review of high-quality randomised controlled trials (RCTs) and assessed all-cause mortality in COPD patients using the Spiriva Respimat Soft Mist Inhaler (RSMI) compared with placebo.
The authors conducted a systematic review of high-quality RCTs with 6522 patients. All included trials were of parallel design with study duration varying from 12 to 52 weeks. The authors conducted various sensitivity analyses to test the robustness of their findings which included using random effects …
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.